General form of registration statement for all companies including face-amount certificate companies

Accounts Payable and Accrued Expenses (Tables)

v3.24.4
Accounts Payable and Accrued Expenses (Tables)
9 Months Ended 12 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Accounts Payable and Accrued Expenses    
Schedule of Accounts Payable and Accrued Expenses

September 30, 

December 31, 

($ in thousands)

2024

    

2023

Accounts payable

$

8,759

$

6,322

Accrued research and development

561

4,118

Accrued compensation

984

2,838

Other (1)

1,757

739

Total accounts payable and accrued expenses

$

12,061

$

14,017

(1) Other includes approximately $1.3 million of accrued consideration for the uBriGene Asset Purchase Agreement, see Note 5.

At December 31, 2023 and 2022, accounts payable and accrued expenses consisted of the following:

December 31,

($ in thousands)

2023

    

2022

Accounts payable

$

6,322

$

6,833

Accrued research and development

4,118

2,782

Accrued compensation

2,838

3,468

Other

739

648

Total accounts payable and accrued expenses

$

14,017

$

13,731